Investment Opportunities

The corporate growth, development and financing are summarized below.

The founders of Biomedical Science Consulting, Inc. (BioSciCon) have incorporated this company to sponsor development of their inventions (biomarker-based in vitro technology) from an idea to commercial products, and to bring these products to the health market to benefit women all over the world.

Along this translational research (from idea – proof of the concept – prototype – feasibility – conditions for use – product – clinical trials to assess safety and efficiency in comparison with standards – manufacturing commercial products – government approval for marketing – sale - revenue), the initial organizational structure of the company grew in parallel: From S-corporation to a limited liability company (LLC) which will continue to grow into private C-corporations and public corporations in the future. Each phase has had specific type of funding.

The R&D phase has been funded by the founders, family and friends, governmental grants (NIH funds via SBIR phase 1 and phase 2 grants and start-up support grant from Montgomery County , MD ). Several other companies and expert-consultants joined this development investing their resources. The R&D continues and co-investment is welcome for co-development of the second generation products: MarkPap® Digital, MarkPap® Wireless and MarkPap® Self. BioSciCon is currently seeking investments for co-development of MarkPap® Wireless to speed-up the development of this most recent BioSciCon product and bring it, as soon as possible, to the benefit of women. The return will be provided from the revenue after sale of the commercial products. This investment will also include sharing the new intellectual property.

In 2005, the business development has reached the LLC phase. MarkPap LLC was incorporated to commercialize the first generation products: MarkPap® Kit and MarkPap® Solution. The worldwide commercialization plan includes two approaches: (1) Licensing patents rights for commercial products, and (2) Sales of products on the market.

(1) Licensing option includes non-exclusive licenses and exclusive, but limited licenses. Limitation is in the scope, territory, time and milestones. Licenses will be granted for reimbursement in form of upfront payment, GMAR and royalty.

(2) Sales of in vitro diagnostic devices is dependable upon manufacturing quality products in upscale industrial quantities, local government approval for marketing, import/export approvals, successful marketing among targeted customers and ability for distribution and sale. Because each and every of these tasks is a program per se, the LLC model has been considered as the most appropriate at this time.

We are glad to announce that Membership in MarkPap LLC is now open for individuals and corporations. LLC recognizes founding members, corporate members, individual members (active and passive), contributors and member-managers. Membership contributions are condition sine qua non for the membership. Contributions could be monetary and non-monetary (services, property, real estate).

The LLC also considers entering into agreements , e.g., strategic alliances or other form of corporate cooperation. The LLC per se does not accept investment into equity, but considers convertible loans up to 1 million and VC investment up to 10 million. Conversion into C-corporation is the model anticipated for receiving investment into equity.

Because the market is huge (approximately 2 billion women are at risk, and the market is anticipated at more than 10 billion dollars per year), our strategy was to disperse it into smaller LLC focused on geographical market areas. This is the reason for incorporating MarkPap Pacific LLC to cover the Wide Pacific Region.

MarkPap LLC welcomes into the business development team Dr. Yatin Thakore, President and CEO SourceIndia, Inc. and Mr. Gerard Viegas, President Information Technologies International, Inc. Their business expertise and connections in the field are considered as the new assets added to the LLC.

Market Needs

There are two markets of consideration, US and World. The US market is mature and is well known: 100 million American women at risk, 50 million Pap tests per year, 20 million American women do not participate, 3.5 million women are Pap test positive and subject to further diagnostic procedures, approximately 2.5 million are found with benign conditions, about 600 thousand are found with HSIL (severe dysplasia) and subject to diagnostic therapy procedures for removal of lesions, about 40,000 intraepithelial cancers (CIN) are removed, 12,000 develop invasive cervical cancers and 4,000 die of this cancer. Pap test has reduced the mortality of cervical cancer for 85% (between years of 1955 and 2005). Recently, this test is combined with HPV testing and new guidelines have included HPV infection in categorization of the degree of the disease. Additional technologies have been added in order to improve the original Pap test. With all these "improvements" the Pap test became expensive and not affordable for the world.

There are 6.5 billion humans living on planet Earth, one half of them are women. At least one half, or 1.7 billion women are at risk for cervical cancer. WHO reports that about 500,000 women develop cervical cancer annually, one half of them die. Three out of four come from the developing countries. Developed countries protect their women with Pap test (in vitro diagnostic medical device for early detection of cervical lesion that, if not removed on time and cured, could progress into cervical cancer). Developing countries cannot afford the cost of Pap test that runs between 40-100 dollars in Maryland, USA. By some estimates, the developing countries cannot afford more than $5.00 per test, the low price that cannot be offered by the current technologies on this market. Alternative methods have been ineffective.

MarkPap technology, because of the biomarker has potentials to become the contemporary replacement for conventional Papanicolaou staining and to enter the Pap test market worldwide as a technology intended for primary screening to detect early cytological signs of lesion that, if untreated, could develop into cervical cancer, but also to detect HPV disease (the human response to HPV infection) and to indicate the need for further diagnostic procedures.